After much thought and discussion, we have decided to discontinue the print version of Communiqué. We will be relaunching it this summer in a new, interactive online experience.

By apriljosselyn • June 22, 2016

Overview The explosive growth of medical knowledge, imaging and technologies, access to medical care, and […]

By Rene Revier • May 22, 2016

Myelodysplastic syndromes (MDS) are malignant hematopoietic stem cell disorders categorized under chronic myeloid malignancies. In this publication, we share our 25 years of experience with primary MDS patients who were evaluated and treated at Mayo Clinic.

By Communiqué Archive • March 7, 2016

Helicobacter pylori (H pylori) infection is among the most common bacterial infections worldwide with approximately one-half of the world’s population infected. Several invasive and noninvasive testing methods are available to detect H pylori infection.

By Communiqué Archive • January 15, 2016

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel biomarker of atherosclerosis and is often referred to by the trademark name “The PLAC Test.” Lp-PLA2 is an enzyme involved with atherosclerotic plaque formation and elevations in plasma Lp-PLA2 concentration and activity are associated with increased risk of cardiovascular disease.

By Communiqué Archive • November 3, 2015

Accurate matching of patients with appropriate blood units is imperative for safe blood transfusion practice. In theory, a computerized bar code-based blood identification system should result in a reduction in transfusion errors.

By Communiqué Archive • September 1, 2015

Inherited cardiovascular diseases have historically been identified most frequently through the patient’s family history. Now, next-generation sequencing technology has taken genetic testing to a new level, allowing assessment of multiple genes and mutations with one test.

By Communiqué Archive • July 1, 2015

Serum thyroglobulin concentrations are used to monitor patients with differentiated thyroid cancer, but may be misleading in the presence of antithyroglobulin autoantibodies and heterophile antibodies. Mayo Medical Laboratories has developed an assay to address this issue by testing first for the presence of thyroglobulin antibodies by immunoassay and, in antibody-positive specimens.

By Communiqué Archive • May 1, 2015

The porphyrias are a group of inborn errors of metabolism caused by enzymatic defects in the heme biosynthetic pathway. Depending upon the specific type of porphyria suspected, certain tests are more informative than other assays.

By Communiqué Archive • March 5, 2015

In 2012, southeastern Minnesota experienced its largest local pertussis outbreak in recent history. In this article, we report the epidemiology and clinical and microbiological characteristics of the pertussis outbreak and examine possible contributing factors.

By Communiqué Archive • January 7, 2015

Lupus anticoagulants are associated with thrombosis, recurrent fetal loss, neurological problems, and cutaneous manifestations. Accurate diagnosis is important considering the potential use of long-term anticoagulant therapy because of the high risk of recurrent thrombosis.

By Communiqué Archive • November 3, 2014

Waldenström macroglobulinemia is a rare disease. Patients present with a spectrum of clinical findings, and many patients do not require treatment initially. This article describes a risk-adapted approach with recommendations on timing and choice of therapy.

By Communiqué Archive • September 4, 2014

Many disorders of the central nervous system previously considered neurodegenerative and untreatable are now recognized as having an autoimmune cause. Detection of neural autoantibodies in serum or spinal fluid is consistent with a diagnosis of an autoimmune encephalopathy, epilepsy, or dementia.

By Communiqué Archive • July 2, 2014